Evidence map›Paper›PMID 21180635›Full record

ArticleTherapeutic advances in neurological disorders2010

Progress in the management of paraneoplastic neurological disorders.

Hamid Sadeghian, Steven Vernino

Abstract read
In one paragraph

Article in Therapeutic advances in neurological disorders, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Therapeutic Plasma Exchange: An Indispensable Therapy for Severe Neurological Condition.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2020
    Article
  9. Article
  10. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review.Annals of clinical and translational neurology · 2016
    Review
  11. Review
  12. Limbic encephalitis and related cortical syndromes.Current treatment options in neurology · 2013
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hamid SadeghianDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Steven Vernino

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paraneoplastic neurological disorders (PNDs) are a rare and diverse group of neurological conditions that can involve any part of the nervous system. Diagnosis is facilitated by finding well-recognized autoantibodies directed against neural antigens in the sera and the cerebrospinal fluid. Identifying and eliminating the underlying malignancy is the mainstay of treatment. Immunomodulatory treatment is gaining more acceptance especially, where a malignancy could not be identified, oncology treatment is completed, or along with cancer treatment. Literature review shows only a handful of systematic prospective case series. Multicenter, prospective controlled clinical trials are needed for future therapeutic advances.

Indexed as

cyclophosphamideintravenous immunoglobulinlimbic encephalitisneuroimmunologyplasma exchange

Identifiers

PMID21180635
PMCPMC3002612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.